Avamax Drug Interactions

The risk of myopathy in patients taking statins is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, niacin or azole antifungals.
Antacids: When atorvastatin and antacid suspension containing magnesium and aluminum hydroxide are co-administered, plasma concentration of atorvastatin decreases approximately by 35%. However, LDL cholesterol reduction is not altered.
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when atorvastatin and colestipol were co-administered. However, reduction of LDL cholesterol was greater when atorvastatin and colestipol were co-administered than when either medicinal product was given alone.
Digoxin: When multiple doses of atorvastatin and digoxin are co-administered, a steady state plasma digoxin concentraton is increased by approximately 20%. Patients taking digoxin should be monitored appropriately.
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased on average by 40% with co-administration of atorvastatin and erythromycin, a known inhibitor of CYP450 3A4.
Oral Contraceptives: Co-administration of atorvastatin and an oral contraceptive increased area under the curve (AUC) values for norethindrone by approximately 30% and of ethinyl estradiol by 20%, respectively. These increases should be considered when selecting a suitable oral contraceptive for a woman taking atorvastatin.
Warfarin: In patients on chronic warfarin treatment, atorvastatin slightly shortens the prothrombin time in the first days of its administration; this time is normalized, however, after 15 days of therapy. In patients receiving warfarin, the prothrombin time should be controlled more often after atorvastatin introduction.
Incompatibilities: Not applicable.